PubMed Central (PMC) Search Page
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 8 |
| 2009 | 30 |
| 2010 | 31 |
| 2011 | 18 |
| 2012 | 23 |
| 2013 | 13 |
| 2014 | 14 |
| 2015 | 23 |
| 2016 | 44 |
| 2017 | 16 |
| 2018 | 15 |
| 2019 | 13 |
| 2020 | 43 |
| 2021 | 36 |
| 2022 | 24 |
| 2023 | 23 |
| 2024 | 270 |
| 2025 | 350 |
| 2026 | 183 |
-
Publication date
-
-
Publication stage
These filters represent the three primary types of content included in the PMC archive: 1) content published in a scholarly journal 2) peer-reviewed author manuscripts accepted for publication in a journal and 3) preprint versions of articles collected through the NIH Preprint Pilot, made public prior to peer review
-
-
Collections
The PMC Open Access Subset includes journal articles and preprints that are made available under license terms that allow reuse. Historical back issues refers to digitized content from print journals made available in PMC through the Biomedical Journal Digitization Projects.
-
"Future Oncol"[Journal]
The embargo is the time during which the publisher retains exclusive rights to distribute articles. Those articles are made freely available on the PMC website after the embargo period has ended. Citations for articles under an embargo period will still display in the PMC results list by default. Choose “Exclude” to prevent embargoed articles from displaying in your results.
-
Vasculogenic mimicry in human cancers associated with chronic high-risk human papillomavirus infection.
- Avila E, Méndez-Pérez EA, Díaz L, García-Quiroz J.
- Future Oncol. 2025 Oct 23;21(28):3677-3689. doi: 10.1080/14796694.2025.2577629.
- PMCID: PMC12674243
Avila E, et al.Future Oncol. 2025.PMCID: PMC12674243 -
A study to learn how well HER3-DXd (patritumab deruxtecan) works and how safe it is in people with previously treated non-small-cell lung cancer that has a mutation in the EGFR gene: a plain language summary of the HERTHENA-Lung01 study.
- Yu HA, Goto Y, Jänne PA.
- Future Oncol. 2026 Oct 12;22(21):2505-2520. doi: 10.1080/14796694.2026.2691681.
- PMCID: PMC13685561
Yu HA, et al.Future Oncol. 2026.PMCID: PMC13685561 -
Patient experiences and unmet needs in diagnosis and treatment of metastatic colorectal cancer: results of a US survey.
- Newcomer K, Clauer J, Ameen K, Incudine A, Mulvey A, Steinberg K, Aquino J, Geiger A, Campbell S, Calabrese A, Tejani M, Shah M.
- Future Oncol. 2026 Oct 10;22(20):2445-2456. doi: 10.1080/14796694.2026.2695213.
- PMCID: PMC13685566
Newcomer K, et al.Future Oncol. 2026.PMCID: PMC13685566 -
Plain language summary of the J-TAIL-2 study results: a study of Japanese patients with extensive-stage small cell lung cancer that followed their treatment with atezolizumab plus chemotherapy over time.
- Miyauchi E, Nishio M, Ohashi K, Osoegawa A, Kikuchi E, Kimura H, Goto Y, Shimizu J, Yoshioka H, Yoshino I, Misumi T, Katakami N, Oki M, Kijima T, Chikamori K, Nishino K, Arai T, Ieda K, Gemma A.
- Future Oncol. 2026 Oct 1;22(20):2371-2383. doi: 10.1080/14796694.2026.2706981.
- PMCID: PMC13685563
Miyauchi E, et al.Future Oncol. 2026.PMCID: PMC13685563 -
Infections in MonumenTAL-1: a plain language summary of talquetamab treatment for relapsed/refractory multiple myeloma.
- Schinke C, Rodríguez-Otero P, van de Donk NWCJ, Lipe B, Lavi N, Rasche L, Cortes-Selva D, Masterson T, Khedkar S, Tolbert J, Kane C, Saber I, Heuck C, Chari A.
- Future Oncol. 2026 Sep 28;22(21):2521-2536. doi: 10.1080/14796694.2026.2722559.
- PMCID: PMC13685558
Schinke C, et al.Future Oncol. 2026.PMCID: PMC13685558 -
Plain language summary of the RELATIVITY-098 study results: nivolumab plus relatlimab given after melanoma is removed by surgery.
- Long GV, Garnett-Benson C, Dolfi S, Ascierto PA, Guo J, Tarhini AA, Chandra S, Muñoz-Couselo E, Del Vecchio M, de Melo AC, Callahan M, Gogas H, Dummer R, Schadendorf D, Koelblinger P, Quereux G, Thomas I, Yu JX, Fisher A, Wang B, Djidel P, Chouzy A, Semaan M, Chen B, Cheong AMY, Tawbi HA.
- Future Oncol. 2026 Sep 22;22(20):2435-2444. doi: 10.1080/14796694.2026.2721180.
- PMCID: PMC13685568
Long GV, et al.Future Oncol. 2026.PMCID: PMC13685568 -
Plain language summary of the ZUMA-5 study of axicabtagene ciloleucel for people with relapsed or refractory slow-growing non-Hodgkin lymphoma.
- Neelapu SS, Nikolajeva O, Jacobson CA.
- Future Oncol. 2026 Sep 16;22(20):2385-2401. doi: 10.1080/14796694.2026.2719395.
- PMCID: PMC13685565
Neelapu SS, et al.Future Oncol. 2026.PMCID: PMC13685565 -
Plain language summary of the KRYSTAL-12 study results: adagrasib for non-small cell lung cancer with KRASG12C mutations.
- Barlesi F, Yao W, Duruisseaux M, Doucet L, Azkárate Martínez A, Gregorc V, Juan-Vidal O, Lu S, De Bondt C, de Marinis F, Linardou H, Kim YC, Jotte R, Felip E, Lo Russo G, Reck M, MichenzIe MF, Yang W, Meade JN, Korytowsky B, Mok TSK; KRYSTAL-12 Investigators.
- Future Oncol. 2026 Sep 16;22(20):2403-2414. doi: 10.1080/14796694.2026.2719409.
- PMCID: PMC13685553
Barlesi F, et al.Future Oncol. 2026.PMCID: PMC13685553 -
Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study.
- Chari A, Touzeau C, Berdeja JG, Oriol A, van de Donk NW, Rodríguez-Otero P, Morillo D, Martinez-Chamorro C, Mateos MV, Costa LJ, Caers J, Rasche L, Krishnan A, Ye JC, Karlin L, Lipe B, Masterton T, Tolbert J, Renaud T, Kane C, Heuck C, Moreau P.
- Future Oncol. 2026 Aug 30;22(20):2415-2434. doi: 10.1080/14796694.2026.2709901.
- PMCID: PMC13685562
Chari A, et al.Future Oncol. 2026.PMCID: PMC13685562 -
The predictive value of dual-energy computed tomography radiomics in microvessel of clear cell renal cell carcinoma.
- Li R, Su X, Li Z, Wang N, Sun H, Ouyang A.
- Future Oncol. 2025 Oct 21;21(28):3629-3638. doi: 10.1080/14796694.2025.2577631.
- PMCID: PMC12674250
Li R, et al.Future Oncol. 2025.PMCID: PMC12674250